5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mechanisms of Erosion of Atherosclerotic Plaques

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose of review

          This review explores the mechanisms of superficial intimal erosion, a common cause of thrombotic complications of atherosclerosis.

          Recent findings

          Human coronary artery atheroma that give rise to thrombosis due to erosion differ diametrically from those associated with fibrous cap rupture. Eroded lesions characteristically contain few inflammatory cells, abundant extracellular matrix, and neutrophil extracellular traps (NETs). Innate immune mechanisms such as engagement of Toll-like receptor 2 (TLR2) on cultured endothelial cells (EC) can impair their viability, attachment, and ability to recover a wound. Hyaluronan fragments may serve as endogenous TLR2 ligands. Mouse experiments demonstrate that flow disturbance in arteries with neointimas tailored to resemble features of human eroded plaques disturbs EC barrier function, impairs EC viability, recruits neutrophils, and provokes EC desquamation, NET formation, and thrombosis in a TLR2-dependent manner.

          Summary

          Mechanisms of erosion have received much less attention than those that provoke plaque rupture. Intensive statin treatment changes the characteristic of plaques that render them less susceptible to rupture. Thus, erosion may contribute importantly to the current residual burden of risk. Understanding the mechanisms of erosion may inform the development and deployment of novel therapies to combat the remaining atherothrombotic risk in the statin era.

          Related collections

          Author and article information

          Journal
          9010000
          8514
          Curr Opin Lipidol
          Curr. Opin. Lipidol.
          Current opinion in lipidology
          0957-9672
          1473-6535
          23 October 2017
          October 2017
          01 October 2018
          : 28
          : 5
          : 434-441
          Affiliations
          [1 ]Department of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
          Author notes
          [* ]Corresponding author: Peter Libby, M.D., Brigham and Women’s Hospital, Harvard Medical School, 77 Ave Louis Pasteur, NRB-741-G, Boston, MA 02115, Phone: 617-525-4383, plibby@ 123456bwh.harvard.edu
          Article
          PMC5676466 PMC5676466 5676466 nihpa912897
          10.1097/MOL.0000000000000440
          5676466
          28682809
          9d023e06-23a1-4d0e-8369-fad460a12287
          History
          Categories
          Article

          Lipid lowering therapy,Intimal hyperplasia,Glycosaminoglycans,Acute coronary syndromes

          Comments

          Comment on this article